Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma

Inclusion Criteria: 1. Following diagnoses are eligible for inclusion in the study: A) Multiple Myeloma with ASCT used as consolidation after first line induction therapy or at first relapse. B) Relapsed/Refractory Hodgkin's disease C) Non-Hodgkin's Lymphomas as follows * Relapsed/Refractory Diffuse large B cell lymphoma * Relapsed/Refractory indolent or relapsed/refractory transformed indolent B cell lymphomas as consolidation after second line therapy * Mantle Cell lymphoma as consolidation after first-line therapy * Peripheral T cell lymphoma as consolidation after first-line therapy or at relapse or primary refractory disease 2. Patients undergoing first ASCT will be eligible for the study. 3. Any prior therapy for the malignancy except CD38 antibody within the last 12 months is allowed. 4. Age ≥18 years 5. Life expectancy of greater than 6 months. Exclusion Criteria: 1. Previously exposure to a CD38 antibody during the last 12 months. 2. Participants who are receiving any other investigational agents concurrently or received any investigational agent within the last 8 weeks. 3. History of severe allergic reactions or anaphylaxis attributed to compounds of similar chemical or biologic composition to Isatuximab. 4. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. 5. Pregnant and Lactating women 6. HIV-positive status due to increased risk of infection when treated with immunosuppressive therapy